Follow the Investment: Where Does Your Money Actually Go?

The Men Behind Wellbeing — Chapter Twelve

Chapter Eleven asked what an investor is actually buying. Now we follow the money. Wellbeing International Foundation says it is raising private capital to support research, international clinical relationships and operational expansion. But before an investor transfers a single pound, dollar or euro, there is a more basic question: which legal entity receives the money, what happens to it after it arrives, and what enforceable claim does the investor have over the assets supposedly being funded?

Chapter Eleven changed the direction of this investigation.

Until then, we had been following people.

Then science.

Then patents.

Then companies.

Then intellectual property.

But eventually every investment story reaches the same point.

The money.

Wellbeing International Foundation has publicly confirmed that it closed the opening tranche of its 2026 capital round and that the round forms part of what it describes as a longer-term funding cadence.

It says its historical funding model has combined private investment, patient revenue and selective philanthropy. It says current capital supports research, its clinical-relationship network, documentation work and operating capacity. (Wellbeing International Foundation)

Those are Wellbeing's statements.

But they don't answer the question this chapter is concerned with.

When an investor sends money to Wellbeing, where exactly does that money go?

Not conceptually.

Not in a presentation.

Not in a marketing narrative.

Legally.

Start With the Bank Transfer

Imagine you are considering investing.

You have been introduced to the science.

You have heard about Cell-Free Therapy.

You have seen the athletes and testimonials.

You have read about the research.

You have been told about international expansion.

You may even have been shown projections describing what the organisation could become.

Then comes the moment that matters.

You are given banking instructions.

Stop there.

Before sending anything, an investor should establish:

What is the exact legal name on the receiving bank account?

Because the brand you believe you are investing in and the legal entity receiving your money are not necessarily the same thing.

That distinction is fundamental.

“Wellbeing International Foundation” Is Not Enough

Wellbeing publicly describes its headquarters as Hamilton, Bermuda. Its contact page likewise identifies Bermuda as its headquarters, while identifying a laboratory operation in Germany. (Wellbeing International Foundation)

That gives us geographical information.

It does not, by itself, tell an investor everything they need to know about the investment vehicle.

An investor should be given the complete legal identity of the entity receiving their capital, including its jurisdiction, registration details and corporate status.

Then the investor should independently verify it.

Because an investment isn't made into a website.

It isn't made into a scientific idea.

And it isn't made into the biographies of the people running the organisation.

It is made pursuant to a legal agreement with a legal entity.

Follow the Money From Day One

Suppose an investor transfers £100,000.

What happens next?

Does that £100,000 remain inside the entity in which the investor acquired an interest?

Or is some of it transferred elsewhere?

For example:

to laboratories;

consultants;

scientists;

clinical partners;

management companies;

research organisations;

marketing companies;

related companies;

directors;

professional advisers;

or other service providers?

There is nothing inherently suspicious about any of those payments.

Businesses have expenses.

International biotechnology organisations inevitably pay external organisations.

The important issue is transparency.

Who gets paid, for what, and on what terms?

This Is Why Related-Party Transactions Matter

One of the documents I would want to see before investing is a complete schedule of related-party transactions.

That means transactions involving companies or individuals connected to directors, shareholders, senior management or other parties with significant influence.

Again, a related-party transaction is not automatically improper.

Many private businesses legitimately transact with connected entities.

But an investor needs to know about them.

If investment capital enters one company and significant amounts subsequently leave through contracts with related organisations, investors need to understand:

who controls those organisations;

what services they provide;

how their fees are determined;

and whether those arrangements were negotiated on normal commercial terms.

Without that information, following the economic value becomes extremely difficult.

Where Does Patient Revenue Go?

This question becomes particularly interesting because Wellbeing says its historical funding model includes patient revenue alongside investment and philanthropy. (Wellbeing International Foundation)

So investors should ask:

Which entity invoices patients?

Which entity receives patient payments?

Which entity pays the laboratory?

Which entity contracts with clinicians?

Which entity owns the patient relationships?

And:

is the company receiving investment the same company receiving the economic benefit from patients?

That distinction could materially affect the value of an investment.

Owning Shares in One Company Doesn't Give You Another Company's Revenue

Consider a simplified example.

Imagine an investor buys shares in Company A.

But patients pay Company B.

Company C owns the intellectual property.

Company D contracts with the laboratory.

And Company E employs or contracts the scientific team.

That structure could be perfectly legitimate.

International businesses frequently operate through multiple companies.

But the investor in Company A needs to understand exactly what Company A owns.

Otherwise, the investor may believe they have exposure to an entire commercial operation when legally they own an interest in only one part of it.

That is why corporate structure matters.

Follow the Assets as Well as the Cash

This investigation has already identified an unresolved intellectual-property question.

Stephen Ray's earlier microvesicle patent family identifies Lydac Neuroscience as the original corporate assignee.

Today, Wellbeing promotes Cell-Free Therapy involving extracellular vesicles.

We have not yet established from the public patent records reviewed a complete assignment chain transferring that historical patent family into Wellbeing.

That doesn't prove Wellbeing lacks rights.

Modern CFT could be different technology.

There could be licences.

There could be later inventions.

There could be proprietary know-how.

But now place that uncertainty inside an investment transaction.

If investors are financing the development of scientific assets, they need to know:

Who owns those assets?

What Does New Investment Actually Create?

Suppose investment capital pays for new research.

That research generates a new process.

Or a new protocol.

Or new clinical data.

Or a patentable invention.

Who owns it?

This is not a theoretical question.

Wellbeing says the current round is supporting continuing research and development. (Wellbeing International Foundation)

Therefore, investor money may contribute to the creation of future scientific value.

An investor should know where that value lands.

Does the investment entity automatically own inventions created through funded research?

Does a scientist own them?

Does a laboratory own them?

Is ownership shared?

Does another company receive a licence?

Are there pre-existing agreements determining those rights?

If investors finance the creation of an asset that legally belongs somewhere else, that is something they need to understand before investing.

The German Laboratory Deserves Its Own Due Diligence

Wellbeing says its Cell-Free Therapy material is processed through a GMP-certified laboratory in Germany. Its public contact information identifies Germany as the laboratory location, and its website repeatedly refers to GMP-certified processing. (Wellbeing International Foundation)

That makes the laboratory commercially important.

So investors should ask:

Who owns the laboratory?

Is it owned by Wellbeing?

Is it independent?

What contractual relationship exists between the laboratory and Wellbeing?

How long does that agreement last?

Can it be terminated?

Does the laboratory own any element of the processing method?

Does it possess manufacturing know-how necessary to produce CFT?

Could Wellbeing move production elsewhere?

And what happens to the business if the laboratory relationship ends?

These are ordinary questions in biotechnology due diligence.

But they become extremely important when the product depends upon specialised biological processing.

The Clinical Network Is Another Asset — But Who Owns the Relationships?

Wellbeing describes an international clinical-relationship network and says CFT is delivered through licensed clinicians. (Wellbeing International Foundation)

That sounds commercially valuable.

But what does “network” mean contractually?

Are clinicians employees?

Independent contractors?

Licensees?

Referral partners?

Customers?

Are there exclusive agreements?

Can clinicians work with competing technologies?

Can relationships be terminated immediately?

Does Wellbeing receive revenue from each treatment?

Does another organisation receive it?

An investor should distinguish between a network that exists through enforceable commercial agreements and a network that depends primarily upon relationships.

Both may have value.

But they are not valued in the same way.

Now Look at the Regulatory Position

This deserves particular attention.

Wellbeing's current regulatory page says that it interprets CFT as aligning with the criteria associated with the US FDA's Section 361 framework.

But the same page also acknowledges:

“Formal FDA guidance specifically addressing CFT has not been published.”

It further states that the regulatory classifications discussed reflect Wellbeing's interpretation. (Wellbeing International Foundation)

That wording matters enormously to an investor.

It does not mean Wellbeing's interpretation is necessarily wrong.

But an interpretation by the company seeking to commercialise a technology is not the same thing as a product-specific determination from the regulator.

That distinction should be understood before assigning value to future US expansion.

What Happens If a Regulator Takes a Different View?

This is where investment risk becomes tangible.

Suppose a future regulator concludes that some aspect of CFT requires a different regulatory pathway.

What happens?

Would additional clinical trials be required?

Would manufacturing requirements change?

Would treatment delivery be restricted?

Would additional approvals be necessary?

How much would that cost?

How long could it take?

Could current investor capital cover it?

I am not predicting that this will happen.

The point is that investors should know whether the business plan has been stress-tested against that possibility.

Because regulatory uncertainty in biotechnology can become financial uncertainty very quickly.

The Science Has a Similar Issue

Wellbeing's 2026 peer-reviewed longevity study is real.

But Wellbeing itself describes it as a single-arm, open-label pilot involving 16 enrolled participants, of whom 14 completed the 17-week programme. The intervention combined lifestyle optimisation, supplements and two administrations of autologous conditioned media. (Wellbeing International Foundation)

That is legitimate early-stage research.

But from an investment perspective, it raises another question.

How much of the company's projected future value depends upon scientific conclusions that still require larger and better-controlled studies?

Because if future valuation assumes stronger clinical validation, further research may require substantially more capital.

Which Brings Us Back to Cash

Biotechnology consumes money.

Research costs money.

Laboratory work costs money.

Clinical studies cost money.

Regulatory work costs money.

International expansion costs money.

People cost money.

And if a company reaches the end of one funding round before reaching the milestone required for the next stage, it may have to raise again.

Wellbeing itself describes its 2026 financing as part of a longer-term funding cadence rather than an isolated event. (Wellbeing International Foundation)

That doesn't automatically make the investment unattractive.

But it means investors should understand the capital requirement.

Ask One Brutally Simple Question

How many months of cash does the current round buy?

Not:

How large is the potential market?

Not:

How exciting is extracellular-vesicle science?

Not:

How many elite athletes have used the programme?

The question is:

How long before the company needs more money?

That figure is called runway.

And without knowing the company's current cash balance, monthly expenditure, committed liabilities and expected revenue, an outside investor cannot calculate it.

Then Ask What Happens When the Money Runs Out

If the business requires another round, existing investors may face several possibilities.

More shares may be issued.

Their percentage ownership may fall.

New investors may demand better terms.

Preference rights may change.

The next round may occur at a lower valuation.

Or sufficient additional capital may not be available.

Again, these are not predictions about Wellbeing.

They are normal venture-investment risks.

But investors should understand precisely how their agreements deal with them.

What Happens in the Worst Case?

This is the uncomfortable part.

But it is the question Chapter Eleven began asking.

Suppose the investment fails.

What can actually be recovered?

Buildings?

Laboratory equipment?

Cash?

Patents?

Licences?

Clinical data?

Trade secrets?

Contracts?

Or is much of the perceived value dependent upon:

future scientific success;

future patients;

future investment;

personal expertise;

commercial relationships;

and the expectation of expansion?

The distinction matters enormously.

Because the value of an investment when everything goes right can look very different from its value when everything goes wrong.

Lydac Makes This Question Impossible to Ignore

There is a historical reason I keep returning to downside protection.

Lydac Neuroscience was also a biotechnology company.

Stephen Ray was associated with its earlier scientific history.

Andrew Chancellor later became one of its directors.

Lydac eventually entered administration.

That does not prove anything improper occurred.

It does not predict Wellbeing's future.

But it demonstrates something every investor already knows:

biotechnology companies can fail.

When they do, investors and creditors discover very quickly which assets were genuinely inside the company and which value existed mainly in expectations.

That is why the unanswered Lydac intellectual-property question remains relevant.

The Word “Foundation” Should Not Replace Due Diligence

There is another psychological issue worth recognising.

The organisation is called:

Wellbeing International Foundation.

The word “Foundation” can sound scientific, institutional or philanthropic.

But investors should judge the investment according to its legal and financial structure, not its name.

Wellbeing itself says its historical funding has included private investment, patient revenue and selective philanthropy. (Wellbeing International Foundation)

Those are economically different activities.

An investor should therefore establish whether the entity receiving their capital is structured as a company, foundation or another legal form, and what economic rights can legally be issued by that entity.

The documents—not the name—provide the answer.

What I Would Demand Before Transferring Money

At this stage, the due-diligence request should become extremely specific.

Before transferring investment capital, I would want documentary answers establishing:

• the exact legal entity receiving the money;

• its registration number and jurisdiction;

• the bank-account beneficiary;

• the security or contractual right being purchased;

• the current shareholders or economic owners and complete cap table;

• the valuation used for the investment;

• existing debt and other liabilities;

• recent financial statements and management accounts;

• cash on hand, monthly burn and expected runway;

• a detailed use-of-funds schedule;

• all material related-party transactions;

• which entity receives patient revenue;

• ownership or contractual control of the German laboratory relationship;

• material agreements with the clinical network;

• the complete IP schedule;

• patent assignments and licences;

• contracts governing Stephen Ray's existing and future intellectual property;

• ownership of research generated using investor capital;

• regulatory opinions supporting planned markets;

• dilution and pre-emption provisions;

• liquidation preferences;

• and the consequences if another financing round cannot be completed.

If those documents exist and answer the questions clearly, investors can evaluate them.

If they don't, that absence itself becomes relevant to the risk assessment.

This Investigation Is Now About Downside

There is an understandable tendency when selling an investment to concentrate on what happens if everything succeeds.

More patients.

More countries.

More clinics.

More research.

More recognition.

Higher valuation.

Potential returns.

But serious due diligence starts at the opposite end.

What happens if it doesn't?

If the science doesn't develop as expected?

If regulation becomes more demanding?

If the laboratory relationship changes?

If a key scientist leaves?

If patient revenue disappoints?

If another capital round cannot be completed?

If the company becomes insolvent?

What does the investor own then?

That is where the real risk becomes visible.

The Public Record Cannot Currently Answer All of This

This point needs to be stated carefully.

Wellbeing says that detailed investment matters are handled privately by its legal and finance team and that it does not publicly discuss its financial structure beyond its published capital announcement. (Wellbeing International Foundation)

That means the absence of these details from the public website does not establish that the information doesn't exist.

It may be contained in confidential investor documentation.

That is exactly why prospective investors should request it.

The concern would arise if material questions remained unanswered after full due diligence had been requested.

Questions for Wellbeing

I would therefore invite Wellbeing International Foundation to clarify the following for prospective investors.

What is the complete legal name and registration details of the entity receiving the 2026 investment?

What instrument or security does an investor receive?

Where is investment capital banked?

Which entity receives patient revenue?

What percentage of investor capital is expected to be spent on research, laboratory services, operations, clinical expansion and professional costs?

Are any material payments made to related parties?

Who owns or controls the German laboratory used for CFT processing?

Which entity owns the CFT process and associated know-how?

Who owns intellectual property created with investor-funded research?

What is the company's current cash runway?

When does management expect another funding round to be required?

What happens to existing investors if additional capital cannot be raised?

And perhaps the most important question:

If Wellbeing ceased trading tomorrow, what identifiable assets would remain available to support the value investors had purchased?

What We Are Not Claiming

This chapter does not establish that investment money is being misused.

It does not establish that funds are being transferred improperly.

It does not establish undisclosed related-party transactions.

It does not establish that Wellbeing is insolvent.

It does not establish that another funding round will fail.

And it does not establish that investors will lose their money.

Those conclusions would require evidence we do not presently have.

What we have established is that the public information available does not answer several questions that are fundamental to understanding the downside risk of the investment.

And when the possible downside includes losing the entire investment, those questions matter.

Conclusion: Don't Follow the Story. Follow the Money.

This investigation began with an extraordinary scientific proposition.

Then came the personalities.

The patents.

The companies.

The insolvency.

The investment round.

And now the money.

Wellbeing says it is raising capital for research and expansion. (Wellbeing International Foundation)

Fine.

Then show investors the structure.

Show them the receiving entity.

Show them the accounts.

Show them the cap table.

Show them the intellectual property.

Show them the laboratory agreements.

Show them where patient revenue lands.

Show them the cash runway.

Show them what their investment actually purchases.

And show them what remains if the optimistic projections never materialise.

Because the greatest danger in a speculative investment isn't necessarily that the science is fraudulent.

It doesn't have to be.

The science can be genuine.

The people can genuinely believe in it.

The opportunity can be exciting.

And investors can still lose everything.

That is why the question is no longer:

How big could Wellbeing become?

The question an investor needs answered first is much less exciting:

Where does my money go — and what do I legally own when it gets there?